Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study
- First Online:
- Cite this article as:
- Forouhi, N.G., Harding, A.H., Allison, M. et al. Diabetologia (2007) 50: 949. doi:10.1007/s00125-007-0604-5
- 1.5k Downloads
The aim of this study was to examine the association between baseline body iron stores and new-onset diabetes.
Subjects and methods
We studied the association between baseline serum ferritin concentration and type 2 diabetes in 360 clinically incident diabetes cases and 758 controls nested within the EPIC (European Prospective Investigation of Cancer)-Norfolk Cohort Study. Serum ferritin levels were categorised into five groups: sex-specific quartiles of the normal range of ferritin and a group with clinically raised ferritin below levels indicative of haemochromatosis.
Baseline serum ferritin was higher among cases than control participants (geometric mean: men 96.6 vs 67.8 ng/ml, respectively, p < 0.001; women 45.9 vs 34.8 ng/ml, respectively, p = 0.005). In analyses adjusted for known risk factors (age, BMI, sex, family history, physical activity, smoking habit) and dietary factors measured by 7-day food diary, the risk of diabetes was markedly elevated in participants with clinically raised ferritin compared with the lowest quartile (odds ratio [OR] 7.4, 95% CI 3.5–15.4). Further adjustment for potential confounding by inflammation (C-reactive protein, IL-6 and fibrinogen) had no material impact on the observed association, while adjustment for hepatic enzymes (alanine aminotransferase and γ glutamyl transferase) and adiponectin attenuated the magnitude of association, but it remained statistically significant (OR 3.2 [1.3–7.6]).
Serum ferritin is an important and independent predictor of the development of diabetes. This finding may have important implications for understanding the aetiology of diabetes.
KeywordsFerritin Hepatic enzymes Inflammation Type 2 diabetes
European Prospective Investigation of Cancer
The nature of the association between abnormal iron storage and the development of type 2 diabetes among individuals without haemochromatosis remains uncertain. In a case–control study nested in a Finnish cohort, men with high iron stores, as measured by the ratio of transferrin receptors to ferritin, had a 2.4-fold elevated risk of incident diabetes compared with those in the lowest quartile . Similarly, in the Nurses’ Health Study of apparently healthy women, elevated ferritin concentration and a lower ratio of transferrin receptors to ferritin were associated with increased risk of diabetes, which was independent of known diabetes risk factors and of inflammation as measured by C-reactive protein (CRP) . These two prospective studies reduce doubt about the temporal sequence which had affected previous cross-sectional or case–control studies [3, 4, 5, 6, 7], but several questions still remain unanswered.
As ferritin is an acute-phase reactant, it is unclear whether adjustment for one marker of inflammation (CRP)  is adequate or whether the association is affected by residual confounding. There is now growing evidence for the association of incident diabetes with both the adipocytokine adiponectin [8, 9] and hepatic function as measured by the hepatic enzymes alanine aminotransferase (ALT) and γ-glutamyl transferase (GGT) [10, 11, 12, 13]. However, their association with ferritin has not been widely studied, nor are there any studies that have adjusted for these markers to test the independence of the ferritin-diabetes association. As previous studies did not distinguish between the clinically normal and clinically raised ferritin levels in the top percentile category of ferritin, a potential dose–response effect of ferritin on diabetes incidence has not been studied. Furthermore, to the best of our knowledge, the published literature on prospective studies is limited to only two studies of incident diabetes [1, 2] plus a recent French study of the combined endpoint of incident non-diabetic hyperglycaemia (n = 200 with impaired fasting glucose) and diabetes (n = 31) . Thus confirmation of the findings is warranted in other settings.
The aims of our study were, therefore, to test the prospective association of serum ferritin with clinically incident diabetes in a population-based cohort study including both men and women, and to test whether this association is independent of a comprehensive range of inflammatory markers, as well as tests of hepatic function and adiponectin.
Subjects and methods
Study design and population
The current case–control study is nested in the European Prospective Investigation of Cancer (EPIC) Norfolk cohort that recruited 25,631 volunteers, aged 40–74 years, from general practices in Norwich and surrounding towns in Norfolk between 1993 and 1997, and has been described in detail previously . In brief, it was a population-based cohort study where participants attended for a baseline health check, completed a postal questionnaire at 18 months of follow-up, and attended for a second health check in 1998–2000. At follow-up (mean 5.1 years, SD 1.7 years) there were 417 clinically incident cases of diabetes. Two sets of control participants were chosen: one set was matched for age, sex, general practice and recruitment date (n = 417), and the other set was additionally frequency matched for BMI (n = 417). For this study we used the combined control participants (n = 834). Of the 417 cases and 834 control participants, data on ferritin were missing for 133; thus the final study population for this study included 360 case and 758 control participants with complete data. The study was approved by the local research ethics committee and participants gave written informed consent.
Ascertainment of incident diabetes
Individuals with self-reported diabetes at baseline were excluded (n = 845). Multiple sources of case ascertainment for new-onset diabetes were as follows: self-report of diabetes from the first and second health check and lifestyle questionnaire; self-report of diabetes-specific medication in either of the two follow-up questionnaires or medication brought to the follow-up health check; or an HbA1c level >7% at either the baseline or follow-up health check. In addition, non-EPIC sources of information included listing of any EPIC-Norfolk participant in the general practice diabetes register, local hospital diabetes register, hospital admissions data at that hospital screened for any diabetes-related admissions among study participants, and Office of National Statistics mortality data with coding for diabetes.
A matrix containing data from the seven sources listed above was drawn up and each record with a positive response in any field was examined to determine whether it qualified for a definition of a new case of diabetes as previously described . A validation exercise of this method of case ascertainment was performed, by reviewing the medical records of case and control participants, in 12 of 35 participating general practices and we found that three sources (general practice registers, HbA1c level and self-report of diabetes) detected 96% of all known cases of diabetes .
Clinical examination to a standard protocol was performed as previously described . Anthropometric measurement included height (m), weight (kg) and waist and hip circumference (cm). BMI was calculated as weight/height2 (kg/m2). A blood test was taken for HbA1c estimation using HPLC on a Bio-Rad Diamat analyser (Bio-Rad, Richmond, CA, USA). Plasma vitamin C was also measured. A detailed health and lifestyle questionnaire was completed at baseline (1993–1997), at 18 months of follow-up and at the second health check (1998–2000). It included items on demography, personal and family history of diabetes among first-degree relatives, smoking, physical activity, medication and diet . In women, a menstrual/menopausal history was recorded and those with their last menstrual period ≥2 years previously were coded as postmenopausal. Information on occupational and leisure-time physical activity was assembled into a four-point physical activity index  and smoking was coded as never, former or current.
At baseline, dietary intake was assessed by a 7-day prospective self-recorded food diary, which asked participants to indicate food content as well as portion size for all food consumed for 7 days. Data were entered using an in-house program DINER (Data into Nutrients for Epidemiological Research) . Nutrient intakes in grams were estimated from the reported food intake and in-house databases .
Frozen portions of serum from case and control participants were selected for simultaneous analysis in 2005. Serum ferritin was measured using a two-step time-resolved fluoroimmunoassay with an AutoDELFIA ferritin kit (Wallac Oy, Turku, Finland). Typical between-batch CV values are 5.8 and 6.7% at 4.6 and 355 μg/l, respectively. Serum high-sensitivity CRP and liver enzymes were measured using a Dade Behring Dimension ARx automated clinical chemistry system (Deerfield, IL, USA), with between batch CV values as follows: CRP 5.0% at 14 mg/l, 2.8% at 120 mg/l; ALT 16.9% at 35 U/l, 6.8% at 470 U/l; GGT 2.9% at 80 U/l, 1.7% at 147 U/l. Serum adiponectin was measured using an AutoDELFIA kit (Wallac Oy) with a two-step time-resolved fluoroimmunoassay, with between-batch CV values of 5.2% at 3.49 μg/ml, 6.95% at 8.85 μg/ml and 11.9% at 15.8 μg/ml.
We calculated mean (SD) or proportion of baseline clinical and metabolic factors and diabetes risk factors among case and control participants, and tested for differences using t or χ2 tests, respectively. The correlations between serum ferritin, inflammatory factors, liver function tests and adiponectin were examined. Skewed variables, including ferritin, were log (natural) transformed to a normal distribution. Participants were classified into five groups according to their sex-specific serum ferritin concentrations, into quartiles of the normal range of ferritin in control participants (groups 1–4), and into a fifth category of clinically raised ferritin (group 5). We defined raised concentrations of ferritin as ≥300 ng/ml for men and ≥150 ng/ml for women, as previously described in an analysis of the Third National Health and Nutrition Examination Survey  and as currently defined by the US National Institutes of Health and National Library of Medicine. These cut-off values are close to the 95th percentile cut-off of 305 ng/ml in men and 165 ng/ml in women in the current study. We excluded individuals (two men, three women), in whom serum ferritin was elevated beyond three times this upper limit of the reference range to reduce the possibility of including those with undiagnosed haemochromatosis. We performed a sensitivity analysis with the alternative upper limit cut-points of 200 ng/ml [20, 21] and 300 ng/ml in women. This latter cut-point was chosen to give the same cut-off in men and women, as some laboratories currently do not use different cut-points by sex.
To examine the distribution of baseline factors across the five groups of baseline ferritin we tested median levels (and interquartile range), with the Kruskall–Wallis test for differences. In logistic regression analyses the dependent variable was incident diabetes vs no diabetes, and the independent variable of interest was ferritin. We performed an unmatched (unconditional) logistic regression analysis and adjusted all analyses for age, sex and BMI to enable the use of all control participants (two control participants for every case), as the frequency matching on BMI was only performed on one set of control participants. In multivariate analyses we constructed models that adjusted for known diabetes risk factors (family history, physical activity and smoking) and potential confounders (dietary factors, inflammatory markers, hepatic enzymes and adiponectin). In women we tested the effect of menopausal status on risk. Tests for departure from linear trend and interaction were conducted using likelihood ratio tests. All analyses were performed using STATA statistical software (version 8.0; Statacorp, College Station, TX, USA).
The distribution of biochemical and dietary factors across sex-specific quartiles of ferritin in the normal range and in the clinically raised ferritin category: the EPIC diabetes nested case–control study (1993–2000)
Group 1 (quartile 1)
Group 2 (quartile 2)
Group 3 (quartile 3)
Group 4 (quartile 4)
Group 5 (raised ferritin)
112.5 to <300
≥300 and <900
63.1 to <150
≥150 and <450
Plasma vitamin C (μmol/l)
Total energy (kJ/day)
Red meat (g/day)
Processed meat (g/day)
Pearson’s correlation coefficients of serum ferritin (ln-transformed) with inflammatory factors, liver function tests and adiponectin in case participants, control participants and all participants: the EPIC diabetes nested case–control study (1993–2000)
Logistic regression analysis of the association of ferritin and diabetes: the EPIC diabetes nested case–control study (1993–2000)
Group 1 (quartile 1)
Group 2 (quartile 2)
Group 3 (quartile 3)
Group 4 (quartile 4)
Group 5 (raised ferritin)
112.5 to <300
≥300 and <900
63.1 to <150
≥150 and <450
OR (95% CI) with models adjusted for:
Age, sex, BMI (Model 1)
Model 1+family history+physical activity+smoking (Model 2)b
Model 2+dietary factors (Model 3)c
Model 3+CRP (Model 4)d
Model 4+fibrinogen+IL-6 (Model 5)d
To reduce the potential confounding effect of obesity we performed all analyses adjusted for BMI, and repeated the analysis with waist circumference in the models, with no change in the magnitude and direction of associations. There was no interaction between BMI and ferritin (p = 0.1). We also repeated analyses with more stringent criteria of exclusion of those with ferritin greater than twice the upper limit of normal (>600 ng/ml in men; >300 ng/ml in women), without any material change in results. None of the control participants had an HbA1c value >6% (control men: HbA1c range 3.5–5.9%, control women: range 3.2–5.9%), thus reducing potential bias due to undiagnosed diabetes in the control group. There was no evidence for statistical interaction between ferritin and any of the inflammatory markers.
In this prospective study we found a strong association between clinically raised ferritin, below the range indicative of clinical haemochromatosis, and development of incident diabetes. The risk was elevated sevenfold in the clinically raised ferritin group compared with the lowest ferritin category. This striking association is of potential importance in understanding the aetiology of type 2 diabetes.
Our study adds new information concerning the association of serum ferritin and incident type 2 diabetes. Unlike previous studies [1, 2] we were able to study the association in both men and women in the same prospective study. There were strong associations of clinically raised ferritin with diabetes, when compared with the whole group of those with normal ferritin, and also when compared with those in the lowest quartile of the ferritin distribution. Our sensitivity analysis showed that this was the case regardless of the cut-point of the upper limit of ferritin in women, in whom there is debate about whether the threshold should be 150 , 200 [20, 21] or the same as in men at 300 ng/ml. We found that elevated ferritin was predictive of diabetes independently of a comprehensive range of risk factors and confounders, where previously only a limited number of confounders were accounted for. Specifically, we found that elevated ferritin was associated with diabetes independently of known risk factors for diabetes (age, BMI, sex, family history, physical inactivity and smoking), as well as dietary factors and alcohol intake measured by food diary. We were able to account for the potential confounding effect of three markers of inflammation (IL-6 and fibrinogen in addition to CRP, which was measured in previous studies). In addition, we also accounted for the potential confounding effect of hepatic enzymes and adiponectin, both of which are now known to be associated with incident diabetes, but their association with ferritin is unclear. Data on fasting glucose are not available in the EPIC-Norfolk study, but we suggest that as non-diabetic hyperglycaemia is likely to be on the causal pathway, it is not likely to be a confounder of the ferritin–diabetes association.
The mechanism for the association between ferritin and type 2 diabetes is not established, but iron deposition in the liver may cause insulin resistance by interfering with the ability of insulin to suppress hepatic glucose production . Iron is auto-oxidised to form highly reactive, lipid-soluble iron–oxygen complexes. These free radicals are powerful pro-oxidants, which can change membrane properties and result in tissue damage [22, 23]. Oxidative stress can also lead to hyperglycaemia through disturbed glucose metabolism . In addition, iron accumulation in hepatocytes may interfere with the insulin-extracting capacity of the liver , and affect insulin synthesis and secretion in the pancreas . Iron excess probably contributes initially to insulin resistance and subsequently to decreased insulin secretion .
The independent association of hepatic enzymes and incident diabetes has now been well described [10, 11, 12, 13]. We found a strong positive correlation between ferritin and the hepatic enzymes, ALT and GGT (r ranging between 0.29 and 0.37, p < 0.0001). This is consistent with the recently reported correlation of 0.37 (p < 0.001) between ALT and serum ferritin among 959 women in a cross-sectional Korean study . It is plausible that iron overload in the liver damages hepatocytes, which in turn would result in elevated transaminases and GGT. Although we did not have access to liver ultrasound or biopsy in our study, a correlation between ferritin level and non-alcoholic fatty liver disease or non-alcoholic steatohepatitis, which is associated with elevated ALT, has been described by others in both obese  and mainly non-obese  individuals. An association between raised hepatic iron concentration and severity of fibrosis in non-alcoholic steatohepatitis has also been reported . Further, Iwasaki et al. also recently described an association between hepatic fat content as measured by computed tomography and ferritin concentration among diabetic individuals .
Although it is well described that hypoadiponectinaemia is predictive of future diabetes [8, 9], there are no previous published reports of an association between serum ferritin and adiponectin levels. We report a strong negative correlation between adiponectin and ferritin (r −0.21 to −0.28, p < 0.0001). Although the mechanism underlying this association is not clear, it is plausible that it works through the recently described association of ferritin with abdominal fat . Thus with our observation of the association between ferritin and diabetes, as well as the association between each of hepatic enzymes (representing hepatic steatosis) and adiponectin with ferritin on the one hand and with diabetes on the other, we believe it is a strength of our study to have accounted for these confounders in our analyses.
Limitations of our study merit consideration. We measured serum ferritin as the only marker of iron storage, but did not measure other markers of iron overload such as transferrin saturation, derived from serum iron concentration and total iron-binding capacity. Although a diagnosis of haemochromatosis is made with combined information on ferritin, transferrin saturation, ALT, liver biopsy and genetic mutations for haemochromatosis, we attempted to exclude the possibility of haemochromatosis in our study by excluding those participants who had ferritin elevated more than threefold above the upper limit of normal. We further applied more stringent criteria by excluding from analysis those who had ferritin levels greater than twice the upper limit of normal, with unaltered findings. Our approach of quartiles among the normal range and the clinically raised ferritin group excluding those with very high levels, offers a clinical utility that highlights that it is those with ferritin elevated above the normal range who are at greatest risk of developing diabetes. Such an approach was not taken by previous studies as they reported results for quintiles of the ferritin distribution , whereby the top quintile included those with levels both below and above the clinically raised level. We have not been able to exclude the possibility that a small number of people with elevated ferritin may have developed haemochromatosis-related diabetes rather than type 2 diabetes, but this is unlikely in the absence of marked hyperferritinaemia, which we were careful to exclude. A further limitation is that we could not specifically measure the known non-genetic causes for iron accumulation, including transfusion iron overload or defective erythropoiesis. Iron overload of undetermined origin includes alcoholic liver disease, non-alcoholic fatty liver disease and chronic hepatitis C infection, although the mechanisms for iron deposition in these conditions is unknown. We did not screen for hepatitis C status, but we would expect very low prevalence in this low-risk population as suggested by the estimated prevalence of between 0.55 and 0.7% in England and Wales in 1991–1996 . We did, however, measure and include in our analyses both alcohol intake and two measures of hepatic function that are markers for non-alcoholic fatty liver disease. Finally, it should be noted that, for pragmatic reasons, in this large cohort study of >25,000 persons, we could only ascertain diagnosed cases of diabetes, thus undiagnosed diabetes was not ascertained biochemically, which would have the overall effect of smaller numbers of cases. We can, however, be reasonably confident that we have minimised the main concern of a potential misclassification of true case participants as control participants in instances of undiagnosed diabetes or failure to self-report diabetes. We can confirm that none of the controls had an HbA1c value >6% (control men: HbA1c range 3.5–5.9%, control women: range 3.2–5.9%), thus reducing potential bias due to undiagnosed diabetes in the control group. Our case ascertainment of diagnosed cases was thorough, with information on self-report supplemented by information from external sources such as general practice records and hospital records as well as death certificates. Our validation of self-report against medical records in 12 of the general practices enabled accurate case ascertainment of clinically diagnosed diabetes.
Our study has several strengths, with its prospective design, inclusion of both men and women, large sample size, and adjustment for a comprehensive battery of risk factors and confounders including measurement of dietary factors by a 7-day food diary. Previous validation studies on this cohort demonstrated that dietary diaries were superior to other methods of assessment of dietary intake [33, 34]. A strength of our study is that as excessive dietary iron intake is a potential reason for variation in iron stores, we adjusted our analyses for dietary iron-related variables (total energy intake, iron intake, and red and processed meat intake), as well as plasma vitamin C, which affects iron absorption, and found that ferritin was associated with diabetes independently of these dietary factors. As ferritin is also an acute-phase reactant and as such reflects not only body iron stores but also subclinical inflammation, we tried to minimise potential confounding by inflammation by adjusting our analyses for three markers of inflammation (CRP, fibrinogen and IL-6), thus making our study more robust than a previous study that adjusted for CRP alone . We were rigorous in our attempts to account for the potential confounding effect of obesity by adjusting all analyses for BMI, and by also adjusting for central obesity (waist circumference).
In conclusion, we have shown prospectively that even modestly elevated ferritin, below levels diagnostic of haemochromatosis or other iron-storage disorders, predicts incident diabetes independently of known risk factors and confounders. These findings have implications for increasing our understanding of the aetiology of type 2 diabetes and merit further study in future studies that help to clarify causality and advance this area of research.
The EPIC-Norfolk cohort is supported by grant funding from Cancer Research UK, the Medical Research Council, the Stroke Association, the British Heart Foundation, the Department of Health, the Commission of the European Union’s Europe against Cancer Programme, the Food Standards Agency, the Department for Environment, Food and Rural Affairs, and the World Health Organization.
Duality of interest
None of the authors reports a duality of interest.